EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

First Trimester Contingent Screening for Aneuploidies with Cell-Free Fetal DNA in Singleton Pregnancies – a Swiss Single Centre Experience

Alice Proto iD, Fabienne Trottmann, Sophie Schneider, Sofia Amylidi-Mohr iD, Florent Badiqué, Lorenz Risch, Daniel Surbek, Luigi Raio, Beatrice Mosimann

Geburtshilfe und Frauenheilkunde · 01.01.2024 · 84 (01) · 68-76

DOI: 10.1055/a-2202-5282 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Geburtshilfe und Frauenheilkunde, erschienen am 01.01.2024. Verfasst von Alice Proto und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynaecology, University Hospital of Bern, University of Bern, Inselspital, Bern, Switzerland. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Switzerland was amongst the first countries to offer cell-free fetal DNA (cffDNA) testing covered by the health insurance to pregnant women with a risk ≥ 1:1000 for trisomies at first trimester combined screening (FTCS). The aim of this study is to evaluate the implementation of this contingent model in a single tertiary referral centre and its effect on gestational age at diagnosing trisomy 21. Between July 2015 and December 2020 all singleton pregnancies at 11–14 weeks of gestation without major fetal malformation were included and stratified according to their risk at FTCS. Statistical analysis was performed by GraphPad Version 9.1 for Windows. 4424 pregnancies were included. Of 166 (3.8%) pregnancies with a NT ≥ 3.5 mm and/or a risk ≥ 1:10 at FCTS, 130 (78.3%) opted for direct invasive testing. 803 (18.2%) pregnancies had an intermediate risk, 692 (86.2%) of them opted for cffDNA first. 3455 (78.1%) pregnancies had a risk < 1:1000. 63 fetuses were diagnosed with trisomy 21, 47 (74.6%) directly by invasive procedures after FTCS, 16 (25.4%) by cffDNA first. Most women choose cffDNA or invasive testing as second tier according to national guidelines. Despite the delay associated with cffDNA testing after FCTS, 75% of all trisomy 21 are still diagnosed in the first trimester with this contingent screening model.

Schlagwörter

Stichwörter der Autor:innen

cell-free fetal DNAfirst trimester screeningnon-invasive prenatal testingtrisomies

Autor:innen und Institutionen

  • Department of Obstetrics and Gynaecology, University Hospital of Bern, University of Bern, Inselspital, Bern, Switzerland.
  • Department of Obstetrics, University Hospital of Basel, University of Basel, Universitätsspital Basel, Basel, Switzerland.
  • Divisions of Clinical Chemistry & Medical Genetics, Dr Risch AG, Liebefeld, Switzerland.

ORCID-Profile: Alice Proto, Sofia Amylidi-Mohr

Zitieren

APA

Proto, A., Trottmann, F., Schneider, S., Amylidi-Mohr, S., Badiqué, F., Risch, L., Surbek, D., Raio, L., & Mosimann, B. (2024). First Trimester Contingent Screening for Aneuploidies with Cell-Free Fetal DNA in Singleton Pregnancies – a Swiss Single Centre Experience. Geburtshilfe und Frauenheilkunde, 84(01), 68-76. https://doi.org/10.1055/a-2202-5282

Vancouver

Proto A, Trottmann F, Schneider S, Amylidi-Mohr S, Badiqué F, Risch L, et al. First Trimester Contingent Screening for Aneuploidies with Cell-Free Fetal DNA in Singleton Pregnancies – a Swiss Single Centre Experience. Geburtshilfe und Frauenheilkunde. 2024;84(01):68-76. doi:10.1055/a-2202-5282

BibTeX
@article{Proto2024,
  author = {Proto, Alice and Trottmann, Fabienne and Schneider, Sophie and Amylidi-Mohr, Sofia and Badiqué, Florent and Risch, Lorenz and Surbek, Daniel and Raio, Luigi and Mosimann, Beatrice},
  title = {First Trimester Contingent Screening for Aneuploidies with Cell-Free Fetal DNA in Singleton Pregnancies – a Swiss Single Centre Experience},
  journal = {Geburtshilfe und Frauenheilkunde},
  year = {2024},
  volume = {84},
  number = {01},
  pages = {68--76},
  doi = {10.1055/a-2202-5282}
}
Kostenlos starten →